Abdullah SİVRİKAYA, Bayram METİN, Esma MENEVSE, Yavuz Selim İNTEPE, Ayşe Yeşim GÖÇMEN

Evaluation of manganese superoxide dismutase and thioredoxin2 levels in asbestos-induced pleural mesothelioma

Asbestos is a mineral known as human carcinogenic material. Exposure to asbestos both in an occupational and environmental way causes asbestosis and mesothelioma. ROS contributes to the development of pulmonary-toxicity induced asbestos.We aimed to determine the levels of important mitochondrial substances such as manganese superoxide dismutase (MnSOD) and Thioredoxin (Trx2) in asbestosis and mesothelioma patients. The study was performed with the patients admitted to outpatient clinics of Chest Diseases and Thoracic Surgery, at Medicine Faculty, Bozok University. Group 1 (healthy control group, n=27): Consisting of healthy individuals (54.18±9.89 years old), Group 2 (patients group, n=34): Evaluation of clinical, pathological and radiological analysis, patients who defined as mesothelioma and/or pleural plaques and asbestosis (60.24±15.24 years old). Patients, who were not biopsied or not available for biopsy due to comorbid diseases, were not included in the study.Biochemical analysis was done in Selcuk University Medicine Faculty Research Laboratories.Serum Trx2 and MnSOD levels were determined by the Elisa method. The results of Trx2 were calculated as pg/µg protein. MnSOD samples were determined as ng/µg protein. MnSOD and Trx2 levels in the patients’ group were statistically lower than the levels of the healthy group (p=0.000, p=0.048), respectively.Trx2 levels were 1.74±0.33 pg/µg protein in a healthy group whereas were 0.89±0.10 pg/µg protein in asbestosis and mesothelioma group. Serum MnSOD levels were 1.38±0.24 and 0.29±0.11 ng/µg protein in healthy and patients’ groups, respectively.These significant changes in malignant mesothelioma patients reflect the impairment of the oxidant-antioxidant balance system. The study presents basic findings for the clinical meaning of mentioned biochemical parameters in mesothelioma patients.

PDF

___

1. Gibbs G, Berry G. Mesothelioma and asbestos. Regul Toxicol Pharmacol. 2008;52;223-31.

2. Turkey asbestos control strategic plan final report. Turk Thorac J. 2015;16:27–52.

3. Liu G, Cheresh P, Kamp DW. Molecular basis of asbestos-induced lung disease.Annu Rev Pathol. 2013;24:161-87.

4. Zalewska-Ziob M, Adamek B, Kasperczyk J, et al. Activity of antioxidant enzymes in the tumor and adjacent noncancerous tissues of non-small-cell lung cancer. Oxid Med Cell Longev. 2019;31:2901840.

5. Kamp DW, Graceffa P, Pryor WA, et al. The role of free radicals in asbestosinduced diseases. Free Radic Biol Med.1999;12:293–315.

6. Huang SXL, Jaurand M-C, Kamp DW, et al. Role of mutagenicity in asbestos fiber–induced carcinogenicity and other diseases. J Toxicol Environ Health. 2011;14:179–245.

7. Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res. 2004;567:1-61.

8. Oberley LW. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother. 2005;59:143-8.

9. Azadmanesh J, Borgstahl EO. A review of the catalytic mechanism of human manganese superoxide dismutase. Antioxidants.2018;7:1-16.

10. Guan Y, Hickey MJ, Borgstahl GE, et al. Crystal structure of Y34F mutant human mitochondrial manganese superoxide dismutase and the functional role of tyrosine 34. Biochemistry. 1998;37:4722–30.

11. Mustacich D, Powis G, Thioredoxin reductase. Biochem J. 2000;346:1-8.

12. Witte A-B, Anestål K, Jerremalm E, et al. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med. 2005;39:696-703.

13. Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy, Cancer Biology Therapy. 2005;4:13- 20.

14. Fuchs J, Podda M, Packer L. Redox-genome interactions in health and disease. JW Goethe University, Frankfurt, ISBN: 0-203-91287-X. Pub. by, Taylor & Francis, e-library. 2005.

15. Miranda- Vizuete A, Damdimopoulos AE, Spyrou G. The mitochondrial thioredoxin system. Antioxid Redox Signal. 2000;2:801-10.

16. Schafer Fq, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 2000;30:1191-212.

17. Burke-Gaffney A, Callister Me, Nakamura H. Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci. 2005;26:398-404.

18. Matsuo Y, Yodoi J. Extracellular Thioredoxin: A therapeutic tool to combat inflammation. Cytokine Growth Factor Rev. 2013;24:345-53.

19. Sung J-H, Gim S-A, Koh P-O. Ferulic acid attenuates the cerebral ischemic injury-induced decrease in peroxiredoxin-2 and thioredoxin expression. Neurosci Lett. 2014;566:88-92.

20. Söderberg A, Sahaf B, Rosén A. Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. Cancer Res. 2000;60:2281-9.

21. Marczynski B, Kraus T, Rozynek P, et al. Association between 8-hydroxy2-deoxyguanosine levels in DNA of workers highly exposed to asbestos and their clinicaldata, occupational and non-occupational confounding factors, and cancer. Mutat Res. 2000;468:203-12.

22. Marczynski B, Kraus T, Rozynek P, et al. Changes in low molecular weight DNA fragmentation in white blood cells of workers highly exposed to asbestos. Int Arch Occup Environ Health. 2001;74:315-24.

23. Hillegass JM, Shukla A, MacPherson MB, et al. Mechanisms of oxidative stress and alterations in gene expression by Libby six-mix in human mesothelial cells. Pratic Fibre Toxicol. 2010;7:26.

24. Batinic-Haberle I, Reboucas JS, Spasojevic I. Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid Redox Signal. 2010;13,877-918.

25. Hasagawa M, Koshikawa I, Takahashi et al. Alterations in manganese, copper, and zinc contents, and intracellular status of the metal-containing superoxide dismutase in human mesothelioma cells. J of Trace Elem Med Biol. 2008;22;248-55.

26. Kahlos K, Pääkkö P, Kurtilla E, et al. Manganese Superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma. British J Cancer. 2000;82:1022-9.

27. Jacquot J-P, Rivera-Madrid R, Marinho P, et al. Arabidopsis thaliana NAPHP thioredoxin reductase. cDNA characterization and expression of the recombinant protein in Escherichia coli. J Mol Biol. 1994;235:1357-63.

28. Gasdaska JR, Berggren M, Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ. 1995;6:1643–50.

29. Holmgren A. Thioredoxin structure and mechanism: conformational changes on oxidation of the active-sitesulfhydryls to a disulfide. Structure. 1995;3:239-43.

30. Becker K, Gromer S, Schirmer RH, et al. Thioredoxin Reductase as a pathophysiological factor and drug target. Eur J Biochem. 2000;267:6118- 25.

31. Amati M1, Tomasetti M, Mariotti L, et al. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat Res. 2008;655:52-8.

32. Otsuki T, Maeda M, Murakami S, et al. Immunological effects of silica and asbestos.Cell MolImmunol. 2007;4:261-8.

33. Onodera T, Momose I, Kawada M. Potential anticancer activity auranofin. Chem Pharm Bull. 2019;67:186-91.

34. Thompson JK, Westborn CM, Macpherson MB, et al. Asbestos modulates thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome activation. Part Fibre Toxicol. 2014;11:1-13.